Clinical Trial

Comparison of Different Dose of Anti-T Lymphocyte Globulin (ATLG) in Haploidentical HSCT for GVHD Prophylaxis

Unknown Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated July 29, 2024 (before its estimated July 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study aims to compare the incidence of graft-versus-host disease (GVHD) in haploidentical hematopoietic stem cell transplant recipients who receive varying doses of anti-T lymphocyte globulin (ATLG) for GVHD prophylaxis. Our primary objective is to determine the optimal dose of ATLG for preventing acute GVHD (aGVHD). Additionally, we plan to evaluate the impact of different doses of ATLG on post-transplant viral infections and other clinical outcomes.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT06525519
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions Hematopoietic Stem Cell Transplantation
Enrollment 104 participants
Start Date 2024-07-31
Primary Completion 2025-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-29